Supplementary Table S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients

Supplementary Table S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients

<p>Supplementary Table 2. Complete table results for all patients (n=201) involved in baseline (C1D1) analysis.</p>

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	Javier Pascual (15018176) (author)
Drugi avtorji:	Miguel Gil-Gil (15052083) (author), Paula Proszek (17141889) (author), Christoph Zielinski (15054460) (author), Alistair Reay (17141892) (author), Manuel Ruiz-Borrego (15048425) (author), Rosalind Cutts (17141895) (author), Eva M. Ciruelos Gil (17141898) (author), Andrew Feber (15124144) (author), Montserrat Muñoz-Mateu (15054469) (author), Claire Swift (17141901) (author), Begoña Bermejo (15037896) (author), Jesus Herranz (15048443) (author), Mireia Margeli Vila (15054472) (author), Antonio Antón (15054475) (author), Zsuzsanna Kahan (17141904) (author), Tibor Csöszi (17141907) (author), Yuan Liu (15054484) (author), Daniel Fernandez-Garcia (17141910) (author), Isaac Garcia-Murillas (15018188) (author), Michael Hubank (15104113) (author), Nicholas C. Turner (17141913) (author), Miguel Martín (15011399) (author)
Izdano:	2025
Teme:	Cancer Cancer Detection and Diagnosis Therapeutic Research and Development Biomarkers Circulating tumor cells/DNA/exosomes Serum biomarkers Breast Cancer Translational Research
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
od: Javier Pascual (15018176)
Izdano: (2025)

Supplementary Figure S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
od: Javier Pascual (15018176)
Izdano: (2025)

Supplementary Figure S3 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
od: Javier Pascual (15018176)
Izdano: (2025)

Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
od: Javier Pascual (15018176)
Izdano: (2025)

Supplementary Figure S5 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
od: Javier Pascual (15018176)
Izdano: (2025)

Supplementary Table S3 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
od: Javier Pascual (15018176)
Izdano: (2025)

Supplemental Table 2 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
od: Morten Lapin (15056728)
Izdano: (2025)

Supplemental Table 1 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
od: Morten Lapin (15056728)
Izdano: (2025)

Supplemental Table 3 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
od: Morten Lapin (15056728)
Izdano: (2025)

Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
od: Andrew A. Davis (15030032)
Izdano: (2025)

Supplementary Figure S7 from <i>NPY</i> Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
od: Katleen Janssens (15053356)
Izdano: (2025)

Supplementary Table S3 from Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma
od: Jun Wang (15051911)
Izdano: (2025)

TS1-9 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
od: Lavanya Sivapalan (15314248)
Izdano: (2025)

Supplementary Table S2 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
od: Sofie H. Tolmeijer (15313251)
Izdano: (2025)

Supplementary Table S1 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
od: Sofie H. Tolmeijer (15313251)
Izdano: (2025)

Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
od: Sofie H. Tolmeijer (15313251)
Izdano: (2025)

Supplementary Data 2 from Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study
od: Ismael Fernández-Miranda (15051932)
Izdano: (2025)

Table S1-S8 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer
od: Ruiyun Zhang (17142498)
Izdano: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
od: Nam Q. Bui (14958210)
Izdano: (2025)

Table 1_Cross-species validation of a 6-miRNA blood signature for Parkinson’s disease: from MPTP mice to human PBMC and serum exosomes.docx
od: Nagyum Jung (22686458)
Izdano: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
od: Nigel Bundred (15046233)
Izdano: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
od: Nigel Bundred (15046233)
Izdano: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
od: Nigel Bundred (15046233)
Izdano: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
od: Nigel Bundred (15046233)
Izdano: (2025)

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
od: Nigel Bundred (15046233)
Izdano: (2025)

Supplementary Fig. S2 from The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in Cancer
od: Sahar Mafi (16721657)
Izdano: (2025)

Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Izdano: (2025)

Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Izdano: (2025)

Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Izdano: (2025)

Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Izdano: (2025)

Figure S5 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Izdano: (2025)

Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Izdano: (2025)

Supplementary Tables 1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
od: Jamunarani Veeraraghavan (16461809)
Izdano: (2025)

Supplementary Video S2A from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
od: Xiaojiang Duan (15439264)
Izdano: (2025)

Supplementary Video S2B from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
od: Xiaojiang Duan (15439264)
Izdano: (2025)

Supplementary Video S2C from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
od: Xiaojiang Duan (15439264)
Izdano: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
od: Milana A. Bergamino (15038015)
Izdano: (2025)

Supplementary Fig. S1 from The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in Cancer
od: Sahar Mafi (16721657)
Izdano: (2025)

Movie S2 from Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics
od: Jill Gallaher (16799594)
Izdano: (2025)

Supplementary Video S1 from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
od: Xiaojiang Duan (15439264)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_an5pio6916h0qsi0jv5j3762c3